6 Monitoring, Bleeding Precautions, and Reversal

Monitoring by medication

Monitoring depends on the medicine. Warfarin is adjusted using PT/INR, while therapeutic Unfractionated heparin is monitored with aPTT or anti-Xa according to institutional protocol.

Direct oral anticoagulants (DOACs) are not routinely titrated using PT/INR or aPTT. Periodic review should consider renal function, blood counts, dose appropriateness, adherence, and interactions. Routine clotting tests can be misleading: normal PT and aPTT do not reliably exclude clinically relevant apixaban activity.

There is no single routine coagulation test used to titrate clopidogrel. If measurement of a factor Xa inhibitor is needed and available, a Drug-calibrated anti-factor Xa assay can help assess its level.

Recognizing a heparin-related risk

A platelet-count decline during heparin exposure, particularly alongside new thrombosis, raises concern for Heparin-induced thrombocytopenia (HIT). A new painful, swollen leg in this setting is a reason for urgent assessment.

If HIT is suspected, stop heparin and urgently notify the responsible clinician for evaluation and an alternative anticoagulation plan. Do not continue or increase heparin simply because the platelet count is low.

Reducing avoidable bleeding risk

Anticoagulants and antiplatelet medicines can contribute to bleeding. Use a soft-bristled toothbrush and an electric razor, check with a health professional before starting over-the-counter medicines or supplements, and tell health professionals about antithrombotic medicines before procedures.

NSAIDs such as ibuprofen can increase bleeding risk. Do not stop or change prescribed antithrombotic therapy on your own. Missed-dose instructions depend on the medicine; do not double a dose unless specifically directed.

Responding to bleeding and injury

Seek urgent medical assessment after a head injury while taking an anticoagulant, even when the person feels well and has no visible bleeding. Disclose the medicine and the time of the last dose. Severe or unusual headache, confusion, weakness, vomiting, or other neurological symptoms are serious warning signs.

Other warning signs include vomiting blood, black or bloody stool, blood in the urine, uncontrolled bleeding, or faintness. Persistent nosebleeding or new extensive bruising while taking clopidogrel needs assessment; apply appropriate local pressure for a nosebleed and contact a clinician promptly. Uncontrolled bleeding or other serious warning signs require emergency care. Do not add an NSAID or stop prescribed antiplatelet therapy without medical advice.

Priorities in major bleeding

Major bleeding requires urgent assessment and treatment. Initial priorities are temporary interruption of antithrombotic treatment as clinically directed, urgent stabilization, and control of the bleeding source. Identify the medicine and last dose, consider kidney function where relevant, review available laboratory results, and assess whether reversal is appropriate. Specialized testing or reversal-agent logistics must not delay resuscitation or local hemostatic care.

Reversal is generally reserved for life-threatening, major, or otherwise uncontrolled bleeding—not routine minor bruising. Reversal decisions are clinician-directed and must account for the patient's clinical situation and the risk of thrombosis.

Reversal approaches by drug

For life-threatening or major warfarin-associated bleeding, Four-factor prothrombin complex concentrate (4F-PCC) with intravenous vitamin K is a standard reversal approach. Plasma may be used if 4F-PCC is unavailable. Urgent resuscitation and control of the bleeding source are also needed.

Protamine reverses Unfractionated heparin; its reversal of low-molecular-weight heparin is incomplete. Idarucizumab is the specific reversal agent for dabigatran. For serious bleeding associated with a factor Xa inhibitor, follow current institutional guidance; 4F-PCC may be considered.

In the United States, Andexxa (andexanet alfa) has not been manufactured for or commercially sold since December 22, 2025. Reversal choices should follow current guidance and be used in appropriate clinical circumstances because reversal can increase thrombotic risk.